# Cambridge Cognition wins £2.1 million contract

- Link: https://www.directorstalkinterviews.com/cambridge-cognition-wins-2.1-million-contract/4121049502
- Published: 2022-02-02T07:03:48+00:00
- Author: Giles

**Cambridge Cognition Holdings Plc** ([LON:COG](https://www.directorstalkinterviews.com/company/cambridge-cognition-holdings-plc/cog.l)),
which develops and markets digital solutions to assess brain health, has announced
that it has been awarded contracts worth £2.1 million to provide cognitive assessments,
electronic diaries, and third-party hardware for two clinical trials in neurodegenerative
disease. Revenue is expected over the next three financial years.

Neurodegenerative disease represents a major global medical need. If treatments 
are not developed soon, then it is estimated that more than 12 million Americans
will be living with neurodegenerative diseases by 2050^(1). Cognitive dysfunction
is a hallmark of many neurodegenerative diseases and so sensitive and specific cognitive
assessment are essential in developing effective treatments. With unrivalled use
in over 2,500 peer-reviewed publications, Cambridge Cognition’s digital cognitive
assessments offer customers outstanding sensitivity and specificity.

A US biotechnology company that has worked with Cambridge Cognition previously is
investigating the effect of a new drug in two neurodegenerative diseases. With some
data being collected in clinic and further insights taken at home, these two clinical
trials are being run in a hybrid or part-virtual manner. 

Cambridge Cognition has been contracted to deliver both elements: providing gold-
standard, computerized cognitive assessments (CANTAB^(TM)) for use in clinics, as
well as daily tests of cognition and a patient diary to track other symptoms via
a mobile app.   This blend of in-clinic and at home monitoring can provide much 
more detailed insights into the development of disease over time and the efficacy
of new pharmaceutical compounds. The electronic diaries for the trials are being
provided using the Company’s electronic Clinical Outcomes Assessment (eCOA) platform.
The Company is also providing third party hardware for use in clinics and at home.

> **Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:**
> “We are delighted to have secured these sizeable contracts with an existing client
> as they progress with further clinical trials of their new drug. They already 
> have an experience of CANTAB™ and so it is also excellent news that our team have
> been successful in demonstrating the value of both our daily cognitive tests and
> our eCOA platform, and with it considerably increasing the value of the contracts.”

Share on:
